研究者情報
検索ページ

（最終更新日：2025-10-07 15:59:40）   イザワ　ナオキ   IZAWA NAOKI   伊澤直樹    所属   医学部医学科 臨床腫瘍学    職種   准教授

■ 学術雑誌 1. 総説・解説　 BRAF V600E変異を有する未治療転移性大腸癌に対するEncorafenib＋Cetuximab＋mFOLFOX6療法と標準治療を比較した国際共同第III相試験（BREAKWATER試験） 2025/08 2. 原著　 A multicenter Phase II study of mFOLFOX6 plus nivolumab for gastric cancer with severe peritoneal metastases: WJOG16322G 2025/07 3. 原著　 Ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum-based chemotherapy: A multicenter observational retrospective study (WJOG13420G) 2025/07 4. 原著　 Prospective Cohort Study of Trastuzumab Biosimilar CT-P6 in HER2-Positive Gastric Cancer: Japanese Real-World Outcomes 2025/06 5. 原著　 Naldemedine for opioid-induced constipation in patients with cancer: A multicenter, double-blind, randomized, placebo-controlled trial 2024/12 6. 総説・解説　 切除可能進行胃癌に対する術前DOS（Docetaxel＋Oxaliplatin＋S-1）療法＋手術＋S-1術後補助化学療法 vs. 手術＋S-1術後補助化学療法の第III相試験（PRODIGY試験）における全生存期間のアップデート 2024/12 7. 原著　 Genomic Profiling of Small Intestine Cancers From a Real-World Data Set Identifies Subgroups With Actionable Alterations. 2024/08 8. 原著　 Phase II study of long-course chemoradiotherapy followed by consolidation chemotherapy as total neoadjuvant therapy in locally advanced rectal cancer in Japan: ENSEMBLE-2 2024/08 9. 原著　 BAYONET trial: A multicenter phase II trial of staged combination with encorafenib + binimetinib + cetuximab following encorafenib + cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer. 2024/06 10. 原著　 Optimizing Organ-Preservation Strategies Through Chemotherapy-Based Selection in Esophageal Squamous Cell Carcinoma: Results From the CROC Multi-Institutional Phase 2 Clinical Trial 2024/06 11. 原著　 Reply to L. Celio et al 2024/05 12. 原著　 The molecular landscape of gastric cancers for novel targeted therapies from real-world genomic profiling. 2024/05 13. 原著　 A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G 2024/03 14. 原著　 Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer 2024/02 15. 原著　 Safety and efficacy of encorafenib, binimetinib, and cetuximab for BRAFV600E-mutant metastatic colorectal cancer: Results of the Japanese expanded access program 2024/02 16. 原著　 Chemotherapy after nivolumab for advanced gastric cancer (REVIVE): a prospective observational study 2023/11 17. 原著　 Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial). 2023/11 18. 原著　 Real-World Treatment Sequencing in Vulnerable Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Study 2023/09 19. 原著　 Perioperative TAS-118 plus oxaliplatin in patients with locally advanced gastric cancer:APOLLO-11 Study 2023/07 20. 原著　 Phase II clinical trial to study the safety and efficacy of combined S-1 + oxaliplatin therapy as neoadjuvant chemotherapy for locally advanced gastric cancer in older patients. 2023/06 21. 原著　 A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial. 2023/05 22. 原著　 Clinical utility of geriatric assessment tools in older patients with gastrointestinal cancer. 2023/05 23. 原著　 A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09). 2023/04 24. 原著　 A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR) 2022/12 25. 原著　 Feasibility of edoxaban for asymptomatic cancer-associated thrombosis in Japanese patients with gastrointestinal cancer: ExCAVE study 2022/12 26. 原著　 Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors 2022/10 27. 原著　 The molecular landscape of pancreatobiliary cancers for novel targeted therapies from real-world genomic profiling. 2022/05 28. 原著　 The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study 2022/04 29. 原著　 A phase II multicenter trial assessing the efficacy and safety of first-line S-1 + ramucirumab in elderly patients with advanced/recurrent gastric cancer: KSCC1701 2022/03 30. 原著　 Clinical Utility of Genomic Profiling Tests in Patients with Advanced Gastrointestinal Cancers 2022/03 31. 原著　 Impact of Body Weight Loss on Survival in Patients with Advanced Gastric Cancer Receiving Second-Line Treatment 2022/03 32. 原著　 免疫チェックポイント阻害薬により出現した皮疹の検討 2021/12 33. 症例報告　 切除不能胃癌に対してSP療法後にConversion　Surgery　を施行し長期生存が得られた1例 2021/12 34. 原著　 Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer 2021/10 35. 症例報告　 Detection of a pinhole-sized bronchoesophageal fistula under bronchoscopic autofluorescence imaging 2021/07 36. 症例報告　 Detection of a pinhole-sized bronchoesophageal fistula under bronchoscopic autofluorescence imaging 2021/05 37. 総説・解説　 化学療法 2021/05 38. 原著　 Impact of Body Weight Loss on Survival in Patients with Advanced Gastric Cancer Receiving Second-Line Treatment 2021/03 39. 原著　 Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer 2021/02 40. 総説・解説　 がん化学療法の薬はや調べノート2020・2021年版 2021/02 41. 総説・解説　 パクラムニボ論文の英訳と監修 2021/02 42. 総説・解説　 口内炎、下痢・便秘、嘔吐・悪心、味覚障害 2021/01 43. 総説・解説　 大腸癌三次治療以降 2021/01 44. 原著　 Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer 2020/12 45. その他　 Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1–4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy 2020/12 46. 原著　 FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer 2020/11 47. 症例報告　 Inferior mesenteric arteriovenous fistula during treatment with bevacizumab in colorectal cancer patient: A case report 2020/11 48. 原著　 Biomarker Analysis in A Randomized Phase 2 Study of Panitumumab Versus Cetuximab in Colorectal Cancer (WJOG6510GTR) 2020/10 49. 原著　 Early tumor shrinkage and depth of response in the second-line treatment for KRAS exon2 wild-type metastatic colorectal cancer: An exploratory analysis of the randomized phase 2 trial comparing panitumumab and bevacizumab in combination with FOLFIRI (WJOG6210G) 2020/09 50. 原著　 Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer 2020/08 51. 原著　 Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer 2020/07 52. 総説・解説　 ラムシルマブ、下痢 2020/06 53. 総説・解説　 上部消化管がん治療State of the art 2020/06 54. 原著　 Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer 2020/04 55. 総説・解説　 分子標的治療　消化器がんにおける分子標的治療薬 2020/02 56. 原著　 Analysis of fistula formation of T4 esophageal cancer patients treated by chemoradiotherapy. 2019/09 57. 原著　 Clinical Implications of Decreased Computed Tomography Value after Ramucirumab in Advanced Gastric Cancer 2019/06 58. 総説・解説　 Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives. 2019/04 59. その他　 抗EGFR抗体薬使用後の薬剤耐性クローンの指数関数的減少：抗EGFR抗体薬のre-challengeへの影響 2019/02 60. 総説・解説　 分子標的薬の最適な治療シークエンス：大腸がん 2018/12 61. 総説・解説　 GI Cancer Selected Papers 2018/10 62. 総説・解説　 ASCOレポート、HIPEC・WJOG7112G(beyond Tmab) 2018/06 63. 総説・解説　 nab-PTX/RAM 2018/06 64. 総説・解説　 抗体薬　ラムシルマブ、アフリベルセプト 2018/06 65. 総説・解説　 胃癌化学療法におけるチーム医療の取り組み 2018/06 66. 総説・解説　 がん化学療法の薬はや調べノート2019・2020年版 2018/05 67. 総説・解説　 切除不能進行・再発胃癌に対する1次治療について 2018/03 68. 総説・解説　 院内システムの運用による多職種連携 2018/03 69. その他　 RIASE試験におけるramucirumabの効果予測バイオーカーの検討 2018/02 70. 総説・解説　 消化器外科専門医の心得 2018 71. 原著　 Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib 2017/12 72. 原著　 がん患者の終末期医療における看取り場所の聴取後の在宅がん緩和医療移行の実態 2017/12 73. 原著　 "Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib" 2017/11 74. 原著　 Exploration of time points and cut-off values for early tumour shrinkage to predict survival outcomes of patients with metastatic colorecatal cancer treated with first-line chemotherapy using a biexponential model for change in tumour size. 2017/11 75. 総説・解説　 「胃がん」Topic Q ＆ A 2017/10 76. 総説・解説　 Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy 2017/09 77. 総説・解説　 GOLD試験(胃がん2次治療におけるweekly paclitaxel±olaparib) 2017/06 78. 総説・解説　 化学療法のレジメン講座 2017/06 79. 総説・解説　 Cancer Board 2017/02 80. 原著　 Identification of FGFR3-TACC3 fusion in esophageal cancer 2017/02 81. 総説・解説　 がん化学療法の薬　はや調べノート2017-2018年版 2017/01 82. 総説・解説　 がん化学療法の薬　はや調べノート2017-2018年版 2017/01 83. 原著　 Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison. 2016/04 84. 総説・解説　 分子標的薬を用いた個別化治療に必要なバイオマーカー 2015/10 85. 総説・解説　 大腸癌 2015/10 86. 総説・解説　 胃がんにおけるrilotumumabのランダム化第Ⅱ相臨床試験とRilomet試験の失敗 2015/08 87. 総説・解説　 胃がんに対する分子標的治療 2015/08 88. 原著　 Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases. 2015/06 89. 総説・解説　 がん分子標的がん治療 2015/05 90. 原著　 Predictability of the anti-tumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer after fluorouracil, irinotecan, and oxaliplatin failure 2015/04 91. 総説・解説　 手足症候群・皮膚障害のマネジメント 2015/03 92. 総説・解説　 病気と薬2016　　大腸癌 2015/03 93. 原著　 Predictability of the anti-tumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer after fluorouracil, irinotecan, and oxaliplatin failure 2015/01 94. 総説・解説　 nab-PTX 2014/10 95. 総説・解説　 消化器がん診療の新たな展開 2014/10 96. 総説・解説　 がん外来化学療法のリアル 2014/07 97. 総説・解説　 胃がん 2014/05 98. 原著　 mTOR阻害薬 2013/10 99. 総説・解説　 集学的治療と化学療法 2013/09 100. 総説・解説　 肝転移を伴う大腸癌に対する全身化学療法 2013/08 101. 総説・解説　 切除不能・再発大腸がんに対する二次治療以降のエビデンス 2012/12 102. 原著　 Gastrointestinal stromal tumor presenting with prominent calcification 2012/10 103. 総説・解説　 切除不能・再発スキルス胃癌に対する化学療法 2012/07 104. 総説・解説　 テムシロリムス 2012/05 105. 総説・解説　 分子標的治療薬による血栓塞栓症 2012/03 106. 総説・解説　 抗体治療 2011/12 107. 原著　 Prospective study of definitive chemoradiotherapy with S-1 and nedaplatin in patients with stage Ⅱ/Ⅲ(non-T4) esophageal cancer 2011/03 108. 原著　 胃穿破部の生検にて診断が得られた多形細胞型退形成癌の１例 2010/08 5件表示 全件表示(108件)

■ 学会発表 1. A retrospective observational study to evaluate the efficacy of trifluridine/tipiracil ± bevacizumab in metastatic colorectal cancer with MSI-high/deficient MMR （口頭発表） 2025/10/16 2. 化学療法が奏功した縦郭進展を伴う胸椎原発悪性骨巨細胞腫の1例 （口頭発表） 2025/09/20 3. 直腸癌に対するtotal neoadjuvant tehrapyの効果を予測するためのctDNA検査 -ENSEMBLE-2試験の結果から- （口頭発表） 2025/03/08 4. 進行性大腸癌に対するRAS/BRAF変異別のCGP検査の臨床的意義 （ポスター） 2025/03/08 5. 膵癌の細胞診検体を用いたデジタルPCRによるKRAS変異同定の臨床的妥当性の検討 （口頭発表） 2025/03/06 6. 通過障害合併Stage IVB食道癌における免疫チェックポイント阻害薬併用化学療法の実用的第2相試験 （ポスター） 2025/03/06 7. Combined Analysis of ENSEMBLE-1 and ENSEMBLE-2 Phase II studies Evaluating TNT in Local Advanced Rectal Cancer in Japan  2024/10 8. Impact of age and single heterozygous UGT1A1 on the safety and efficacy of first-line FOLFIRI or FOLFOXIRI in combination with ramucirumab (RAM) for metastatic colorectal cancer (mCRC): subgroup analyses of WJOG9216G (RECAST)  2024/09 9. 局所進行下部直腸癌における術前治療の治療成績と展望 （口頭発表） 2024/07/19 10. 切除不能進行再発大腸癌（mCRC）における血漿を用いた包括的ゲノムプロファイリング（CGP）のRAS/BRAF変異別の意義 （口頭発表） 2024/07/12 11. 通過障害を合併したStage IVB食道癌に対する治療選択と臨床転帰の評価 （ポスター） 2024/07/04 12. A multicenter single-arm phase II study examining the efficacy of TNT for locally advanced rectal cancer: ENSEMBLE-2 （ポスター） 2024/06 13. Phase 1b study of futibatinib plus pembrolizumab with or without chemotherapy in patients with esophageal carcinoma: Updated results of antitumor activity. （ポスター） 2024/05 14. Anti-EGFR therapy for RAS mutant mCRC without RAS mutations in ctDNA after 1st or 2nd-line chemotherapy: JACCRO CC-17 （口頭発表） 2024/02/24 15. Clinical significance of plasma-based comprehensive genomic profiling in metastatic colorectal cancer by RAS/BRAF status （口頭発表，一般） 2024/02/24 16. 患者と主治医の抗がん剤による副作用のつらさと休薬希望度の差に関する意識調査 （口頭発表） 2024/02/24 17. 進行頸部食道扁平上皮癌患者に対してDocetaxel/Cisplatin/5-FU と強度変調放射線治療 IMRT を同時併用する根治的化学放射線療法の第Ⅱ相試験 （口頭発表） 2024/02/24 18. A feasibility study to evaluate clinical utility of stress data collection in cancer patients treated with chemotherapy （口頭発表） 2024/02/22 19. A prospective observational study of MSI screening in chemotherapy-naive advanced gastric cancer: WJOG13320GPS （口頭発表） 2024/02/22 20. Clinical course of skin rashes caused by neoadju-vant gemcitabine plus S-1 for resectable pancre-atic cancer （口頭発表） 2024/02/22 21. The clinical validity of droplet digital PCR to identify KRAS mutations using blood or cytology specimens in pancreatic cancer （口頭発表） 2024/02 22. An observational study on treatment patterns and outcomes among patients with metastatic or recurrent esophageal cancer: Real-world data and empirical analyses in Japan (POME). （ポスター） 2024/01/20 23. The efficacy of anti-EGFR therapy for RAS mutant metastatic colorectal cancer patients with RAS mutation negative in circulating-tumor DNA after 1st or 2nd-line chemotherapy （ポスター，一般） 2023/10/22 24. 免疫チェックポイント阻害薬による間質性肺炎に対する治療実態調査 （口頭発表） 2023/10/21 25. A randomized phase II study comparing S-1 plus oxaliplatin with S-1 monotherapy for elderly patients with advanced gastric cancer: WJOG8315G （ポスター） 2023/10 26. RAS status in circulating-tumor DNA after chemotherapy in RAS mutant mCRC: the RASMEX study (JACCRO CC-17) . （口頭発表） 2023/07/01 27. 切除不能なvulnerable大腸がん患者に関する実態調査：治療パターンと2次治療移行に関連する因子の検討 （ポスター） 2023/03/18 28. 高齢者切除不能・再発胃癌に対するS-1単剤療法とS-1/L-OHP併用療法のランダム化第２相試験 （口頭発表） 2023/03/18 29. A study to evaluate the clinical utility of stress data collection in cancer patients treated with chemotherapy （ポスター） 2023/03/17 30. がん薬物療法患者におけるストレスデータ収集の有用性に関する研究 （ポスター） 2023/03/17 31. BRAF V600E変異型切除不能進行・再発大腸癌に対するFOLFOXIRI+/-Bevacizumab療法とDoublet療法の有効性及び安全性に関する後方視的検討 （口頭発表） 2023/03/16 32. RAS変異型切除不能進行・再発大腸癌患者における化学療法後のctDNA中RAS遺伝子変異ステータス：RASMEX study (JACCRO CC-17) （口頭発表） 2023/03/16 33. 切除不能なvulnerable大腸がん患者に関する実態調査：1次治療症例210例の検討 （口頭発表） 2023/03/16 34. 切除不能進行大腸癌におけるCDC37遺伝子発現のレゴラフェニブ療法の効果予測 （口頭発表） 2023/03/16 35. 胃癌患者における免疫関連有害事象の予測因子としての自己免疫疾患関連抗体の臨床的意義 （口頭発表） 2023/02/25 36. Treatment for elderly gastric cancer patients-Geriatric assessment and clinical outcomes- （口頭発表） 2023/02/24 37. 胃癌ゲノムプロファイリングによるdruggable alterationの同定 （口頭発表） 2023/02 38. 高齢胃癌患者における高齢者機能評価と臨床経過 （口頭発表） 2023/02 39. リアルワールドデータ（RWD）から見た小腸癌のゲノムランドスケープ （口頭発表） 2022/10 40. 当院における抗EGFR抗体薬投与患者に対する診察前面談の取り組み （口頭発表） 2022/10 41. 食道扁平上皮癌・胃食道接合部癌におけるctDNAを用いた治療戦略 （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2022/09/25 42. 切除可能大腸がん高齢患者の高齢者機能評価と臨床経過 （ポスター） 2022/06/18 43. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer (mCRC). （ポスター） 2022/06/04 44. An observational study of health-related quality of life (HRQoL) with electronic patient-reported outcome (ePRO) monitoring during nivolumab therapy for advanced gastric cancer as the 3rd or later line treatment: NIVO-G QoL study. （ポスター） 2022/06 45. A phase II, non-randomized, prospective trial of biweekly nab-paclitaxel in combination with ramucirumab for patients with previously treated advanced gastric or gastro-esophageal junction cancer: B-RAX trial (JACCRO GC-09)  2022/03/02 46. Observational study to evaluate RAS status in ctDNA for mCRC patients with RAS mutant tumor: RASMEX study(JACCRO CC-17). （ポスター） 2022/02 47. Somatostatin receptor: a potential new therapeutic target for primary mucinous neoplasm of the appendix. （口頭発表） 2022/02 48. A phase II, non-randomized, prospective trial of biweekly nab-paclitaxel in combination with ramucirumab for patients with previously treated advanced gastric or gastro-esophageal junction cancer: B-RAX trial (JACCRO GC-09)  2022/01/21 49. Genomic landscape in small intestine cancer from real-world data (RWD) of clinical genomic testing.  2022/01/20 50. An observational study to evaluate RAS mutations in circulating tumor DNA after standard chemotherapies for metastatic colorectal cancer patients with tumors harboring RAS mutation: RASMEX study (JACCRO CC-17). （ポスター） 2022/01 51. 聖マリアンナ医科大学病院における両立支援相談体制の構築と進捗 （口頭発表，特別・招待講演等） 2021/11/29 52. Genomic landscape in advanced gastric cancer from real-world data (RWD) of clinical genomic testing （ポスター，一般） 2021/09/21 53. Placebo-controlled, double-blinded phase Ⅲ study comparing dexamethasone on day 1 with dexamethasone on days 1 to 4, with combined neurokinin-1 receptor antagonist, palonosetron, and olanzapine in patients receiving cisplatin-containing highly emetogenic chemotherapy: SPARED Trial  2021/09/17 54. 免疫チェックポイント阻害薬により出現した皮疹の検討 （口頭発表，一般） 2021/07/10 55. A multicenter phase II trial of trifluridine/thipiracil in combination with cetuximab in RAS wild-type metastatic colorectal cancer patients refractory to prior anti-EGFR antibody : the WJOG8916G trial  2021/06/30 56. Gene alterations in ctDNA related to the resistance mechanism of anti-EGFR antibodies and clinical efficacy outcomes of anti-EGFR antibody rechallenge plus trifluridine/tipiracil in metastatic colorectal cancer patients in WJOG8916G trial  2021/06/30 57. The Implication of Neurofilament light chain and Galectin-3 in paclitaxel-induced peripheral neurotoxicity for patients with advanced gastric cancer  2021/06/24 58. Genomic alterations for novel targeted therapies in pancreatobiliary cancers from real-world data （ポスター，一般） 2021/06/04 59. The Implication of Neurofilament light chain and Galectin-3 in paclitaxel-induced peripheral neurotoxicity for patients with advanced gastric cancer  2021/05/29 60. 免疫チェックポイント阻害薬の免疫関連有害事象に対する治療前の抗体検査の意義. （口頭発表，一般） 2021/05/29 61. 免疫チェックポイント阻害薬による中枢神経領域の免疫関連有害事象に関する検討 （口頭発表，一般） 2021/05/22 62. 切除不能胃癌に対してＳＰ療法後にcomversion surgery を施行し、長期生存が得られた1例 （口頭発表，一般） 2021/05/21 63. Bi-weekly nab-paclitaxel and ramucirumab therapy for advanced gastric cancer: JACCRO GC-09 trial （口頭発表） 2021/03/04 64. Gene profiling of circulating tumor DNA (ctDNA) in RAS wild-type mCRC patients who are refractory to anti-EGFR antibody  2021/02/19 65. 進行固形がん患者における免疫チェックポイント阻害薬導入前の抗体検査と免疫関連有害事象との関連性  2021/02/19 66. A translational study to evaluate genomic markers and concordance with circulating-tumor DNA and circulating tumor cells to predict clinical outcomes in gastrointestinal and pancreatobiliary cancers: Valor trial. （ポスター） 2021/01/15 67. Multi-gene panel testing in patients with gastro-intestinal cancers: A retrospective study. （口頭発表，一般） 2020/10/23 68. 高齢者胃癌に対する治療の工夫 （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2020/10/22 69. 104P Angiogenesis-related factors and clinical outcomes in combination therapy with paclitaxel (PTX), ramucirumab (RAM) plus nivolumab (Nivo) for advanced gastric cancer (AGC)  2020/09/20 70. 血管新生阻害薬による化学療法中に下腸間膜動静脈瘻を合併した大腸癌症例 （ポスター，一般） 2020/08/11 71. A phase I/II study of nivolumab, paclitaxel, and ramucirumab as second-line in advanced gastric cancer. （ポスター） 2020/01/24 72. Analysis of early tumor shrinkage (ETS) and depth of response (DpR) in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line FOLFIRI plus panitumumab (Pani) or bevacizumab (Bev): Results from a randomized phase II WJOG6210G trial.  2020/01/24 73. The treatment strategy of the second-line chemotherapy for metastatic colorectal cancer (mCRC) patients (pts) with early progression in the first-line chemotherapy with bevacizumab (BEV), BEV beyond progression (BBP), or non-BBP.  2020/01/24 74. Vascular endothelial growth factor (VEGF)-D and clinical outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line FOLFIRI plus bevacizumab (Bev): A biomarker study of the WJOG 6210G trial.  2020/01/24 75. Association of gastric acid suppression with efficacy of immune checkpoint inhibitors (ICIs) in advanced cancer patients （口頭発表） 2019/10/24 76. Prognostic and predictive impact on FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer （口頭発表） 2019/09/29 77. Association of gastric acid suppression with efficacy of immune checkpoint inhibitors （口頭発表） 2019/07/20 78. 2nd line bevacizumab(BEV) continuation chemotherapy(Cx) beyond early progression for metastatic colorectal cancer(mCRC)  2019/07/19 79. Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second-line treatment in patients with advanced gastric cancer  2019/07 80. Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer  2019/06 81. Phase III Study of Comparing Dexamethasone on Day 1 with Day 1-4 with Combined Nurokinin-1 Receptor Antagonist, Palonosetron and Olanzapine in Cisplatin-based Chemotherapy:SPARED Trial  2019/06 82. 胃がん栄養 （ポスター） 2019/03/08 83. Antibiotics may enhance the efficacy of gemcitabine treatment for advanced pancreatic cancer （ポスター） 2018/10/21 84. Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer  2018/10/21 85. The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Efficient Identification of Cancer Genome Alterations in Advanced Pancreatic Cancer Cohort  2018/10/21 86. Dynamic change of immune-related gene expression status during chemoradiotherapy in locally advanced esophageal cancer （ポスター） 2018/10/20 87. Regorafenib療法のラーニングカーブ評価 （ポスター） 2018/07/20 88. The Nationwide Cancer Geome Screening Project in Japan, SCRUM-Japan Advanced Biliary Tract Cancer Cohort  2018/06 89. Phase I study of the anti-heparin binding-EGF antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer （ポスター） 2018/04 90. Plasma VEGF-A (pVEGF-A) level in efficacy analysis of metastatic colorectal cancer patients (mCRC) treated with mFOLFOX6/XELOX plus bevacizumab (BV) (WJOG7612GTR).  2018/01/18 91. Clinical Implication of Morphological Changes of Ramucirumab in Metastatic Gastric Cancer  2017/07/27 92. Early morphologic change (EMC) caused by regorafenib (REGO) in patients (pts) with metastatic colorectal cancer (mCRC) （一般） 2017/07 93. The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced gastrointestinal cancer.  2017/06/02 94. Identification of a FGFR3-TACC3 fusion in esophageal cancer  2017/04/01 95. Predictability of survival outcome by early tumor shrinkage (ETS) at 8 weeks with cutoff value of 20% in metastatic colorectal cancer (mCRC) patients treated with mFOLFOX6 plus bevacizumab (bev) or FOLFIRI plus bev as first-line chemotherapy (1st-CTx): validation in the phase III WJOG4407G trial  2017/01 96. SCRUM-Japan GI-Screen:Efficient Identification of Cancer Genome Alternation in Non-Colorectal Gastrointestinal Cancer （ポスター） 2016/07/29 97. 切除不能進行・再発大腸癌に対するサルベージライン化学療法（regorafenib, TAS102）の後方視的検討 （口頭発表，一般） 2016/07/28 98. The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced non-colorectal (Non-CRC) gastrointestinal cancer.  2016/06 99. 聖マリアンナ医科大学病院におけるシスプラチンによる腎障害の実態と軽減対策の効果  2016/03 100. Evaluation timing and cutoff value of tumor size (TS) ratio by using tumor growth inhibition (TGI) model to predict overall survival (OS) in metastatic colorectal cancer (mCRC) patients received first-line chemotherapy (CTx)  2015/09 101. Impact of worsening in patient reported symptomatic adverse events (AEs) on deterioration of daily assessed quality of life (QOL) in cancer patients receiving initial chemotherapy; prospective exploratory study  2015/09 102. T4食道癌の瘻孔形成における臨床経過について  2015/07 103. 初回化学療法例における日々の患者報告アウトカム(patient reported outcome)に基づく 自覚的副作用の悪化によるQOLへの影響  2015/07 104. 外来化学療法における発熱性好中球減少症の一症例  2015/07 105. 遠隔転移を有する進行食道扁平上皮癌に対する化学放射線療法の経口摂取改善における臨床的意義  2015/07 106. "N2c,N3または鎖骨上窩リンパ節転移を伴うN2bを有する局所 進行頭頸部扁平上皮癌に対するTPF導入化学療法"  2014/07/17 107. がん患者の看取る場所についての検討：在宅診療に移行した患者が、病院に再入院する理由を中心に  2014/07/17 108. HERC2 interacts with Claspin and regulates replication fork progression and origin firing. （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2011/10/03 109. Identification of DNA methylation changes in esophageal cancer before/after chemoradiation therapy using a MCA-microarray and bisulfate pyrosequencing  2010/06/04 110. 当院における食道癌に対する5-FU/Nedaplatinの化学放射線療法の治療成績  2010/04/01 5件表示 全件表示(110件)